If other countries paid their fair share for novel medicines, we’d all have more of them. New research from Precision Health Economics finds that if government price controls in non-U.S. OECD countries were lifted, the number of new treatments available would increase by 9 to 12 percent by 2030 (equivalent to 8 to 13 new drugs in that year), potentially increasing the life expectancy of the average American 15-year-old today by 0.8 to 1.6 years.
